In the course of this review, we refer to newly-emerging indications in both the field of cochlear implants (bimodal stimulation, implantation in patients with residual hearing, bilateral implants, etc) and in the area of ABI in patients with tumoural disease previously treated with radiosurgery or patients with non-tumour pathologies presenting malformations or bilateral cochlear ossification.
Review of Audiometric Criteria in Treatment of Neurosensorial Deafness With Hearing Aids and Implantable Hearing Devices
 
  Key words
 
 
  
   Hearing loss
  
 
 
  
   Hearing aids
  
 
 
  
   Auditory implants
  
 
<dis>Sensorineural hearing loss</dis> has a high incidence in our population; as a matter of fact, 50 % of people above 75 years of age suffer this impairment.
Due to the advances in the devices to alleviate this condition and their verified efficacy, it is now appropriate to review the indications for these devices and provide a detailed description of the audioprosthetic systems used.
These systems can be classified as external non-implantable devices (hearing aids) and implantable prostheses.
The latter can be sub-divided into active implants in the external ear or middle ear, cochlear implants, and auditory brainstem implants (ABI).
Indications for each group are determined by the type and location of the underlying condition as well as by the anatomic, functional, and social characteristics of each patient.
It must be stressed that the selection and monitoring of the treatment is up to the specialist.
Generally speaking, an attempt is made to facilitate the integration of the <dis>hypoacusic</dis> patients to their sound setting by enhancing their understanding of the spoken word and restoring binaurality, while at the same time, seeking to retain the plasticity of central auditory routes through the stimulation provided by any of these systems.
In the course of this review, we refer to newly-emerging indications in both the field of cochlear implants (bimodal stimulation, implantation in patients with residual hearing, bilateral implants, etc) and in the area of ABI in patients with tumoural disease previously treated with radiosurgery or patients with non-tumour pathologies presenting malformations or bilateral cochlear ossification.
Sensorineural hearing loss has a high incidence in our population; as a matter of fact, 50 % of people above 75 years of age suffer this impairment.
Due to the advances in the devices to alleviate this condition and their verified efficacy, it is now appropriate to review the indications for these devices and provide a detailed description of the audioprosthetic systems used.
These systems can be classified as external non-implantable devices (hearing aids) and implantable prostheses.
The latter can be sub-divided into active implants in the external ear or middle ear, cochlear implants, and auditory brainstem implants (ABI).
Indications for each group are determined by the type and location of the underlying condition as well as by the anatomic, functional, and social characteristics of each patient.
It must be stressed that the selection and monitoring of the treatment is up to the specialist.
Generally speaking, an attempt is made to facilitate the integration of the hypoacusic patients to their sound setting by enhancing their understanding of the spoken word and restoring binaurality, while at the same time, seeking to retain the plasticity of central auditory routes through the stimulation provided by any of these systems.
In the course of this review, we refer to newly-emerging indications in both the field of cochlear implants (bimodal stimulation, implantation in patients with residual hearing, bilateral implants, etc) and in the area of ABI in patients with tumoural disease previously treated with radiosurgery or patients with non-tumour pathologies presenting malformations or bilateral cochlear ossification.
In the course of this review, we refer to newly-emerging indications in both the field of cochlear implants (bimodal stimulation, implantation in patients with residual hearing, bilateral implants, etc) and in the area of ABI in patients with tumoural disease previously treated with radiosurgery or patients with non-tumour pathologies presenting malformations or bilateral cochlear ossification.